AlphaMadera's AlphaVal page computes AIM ImmunoTech Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag AIM as undervalued, fairly valued, or overvalued.

What is AIM ImmunoTech Inc.'s fair value?

Fair value for AIM is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value AIM?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from AIM's most recent reported fundamentals.

AIM - AIM ImmunoTech Inc.

Price: -- -- | CONSENSUS: Buy DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: AIM financials appear to be in a foreign currency (EPS $-9 vs. price $0.65). Cannot value.